Standout Papers
Citation Impact
Citing Papers
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up
2010
Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
2009 StandoutScienceNobel
IL-23 plays a key role in Helicobacter hepaticus –induced T cell–dependent colitis
2006
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
2006
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
The microbiota regulates type 2 immunity through RORγt + T cells
2015 StandoutScienceNobel
Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells
2006
Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation
2002
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
2005
Maintenance treatment of Crohn's disease
2003
Cancer risk in patients with inflammatory bowel disease
2001 Standout
Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial
2006
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
2006
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections
2005 StandoutNatureNobel
Infliximab for acute, not steroid-refractory ulcerative colitis
2004
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease
2008
Inflammation and cancer
2002 StandoutNature
Crohn’s disease and the NOD2 gene: a role for paneth cells
2003
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Management of Crohn's disease in adults
2001
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
2001
Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut
2008
Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells
2005
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
2001
A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease
2007
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County
2004
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Host tissue determinants of tumour immunity
2019
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
2008
Unravelling the pathogenesis of inflammatory bowel disease
2007 StandoutNature
Long-term treatment of rectovaginal fistulas in Crohn’s disease: Response to infliximab in the ACCENT II Study
2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
2004
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
2000
Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease.
1990
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
2007
AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
2010
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
2005
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Clinical Experience With Infliximab Therapy in 100 Patients With Crohn's Disease
2000
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Comparative Tolerability of Treatments for Inflammatory Bowel Disease
2000
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice
2007
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
2014
Crohn's disease
2012 Standout
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
2002
Layers of mutualism with commensal bacteria protect us from intestinal inflammation
2006
CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial
2006
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
2006
Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
1999
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience
2001
Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
2002
Inflammatory bowel disease: cause and immunobiology
2007 Standout
A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease
2005
Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer
2002
Review article: safety of infliximab in clinical trials
1999
Infliximab in Crohn's Disease: First Anniversary Clinical Experience
2000
Inflammatory Bowel Disease
2009 Standout
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis
2004
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
2008
Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease
2002
Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression
2005
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
2001
Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2006
Colonic epithelial cell mediated suppression of CD4 T cell activation
2004
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
2009
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula
2009
Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune Pathology
2006
Predictors of Crohn’s Disease
2006
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008
The eight human “canonical” ribonucleases: Molecular diversity, catalytic properties, and special biological actions of the enzyme proteins
2010
Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis
2008
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
2008
Microbial Influences in Inflammatory Bowel Diseases
2008
Inflammatory Bowel Disease
1991 Standout
Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2006
A Simple Classification of Crohnʼs Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
2000 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Oral tolerance
2011
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 Standout
Ankylosing spondylitis
2007 Standout
Regulatory T cells and cancer
2007
Inflammatory Bowel Disease
2002 Standout
Expression and functional characterization of FOXP3+CD4+ regulatory T cells in ulcerative colitis
2006
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
2003
Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease
2009
Intestinal mucosal barrier function in health and disease
2009 Standout
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
2012
Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis
2004
Distribution and Manifestations of Inflammatory Bowel Disease in Asians, Hispanics and African Americans: A Systematic Review
2009
Certolizumab Pegol for the Treatment of Crohn's Disease
2007
The immune response of Drosophila
2003 StandoutNatureNobel
Endosonographic Evidence of Persistence of Crohn's Disease-Associated Fistulas After Infliximab Treatment, Irrespective of Clinical Response
2002
Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study
2011
Diagnostics of Inflammatory Bowel Disease
2007
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
2006
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Regulatory T Cells Reinforce Intestinal Homeostasis
2009
Clinical trials of antibody therapy
2000
Medical therapy for ulcerative colitis 2004
2004
A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes
2007
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
2006
Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
2005
Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease
2001
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM
1993 Nature
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation?
2005
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
2006
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
2011 StandoutNobel
Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab
2000
Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells
2009
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
1999
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
2008
The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells
2012
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
2009
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial
2003
Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity
2011
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM
1993 Nature
Molecular pathogenesis of inflammatory bowel disease: Genotypes, phenotypes and personalized medicine
2007
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease
2011
The Genetics of Inflammatory Bowel Disease
2007
Mucosal vaccines: the promise and the challenge
2006
Does Mycobacterium avium subspecies paratuberculosis cause Crohn’s disease?: Table 1
2005
An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
2001
The Primary Immunodeficiencies
1995
XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease
2008 Standout
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
2002
Oral tolerance in the absence of naturally occurring Tregs
2005
Tumor necrosis factor or tumor promoting factor?
2002
Regulation by HIV Rev depends upon recognition of splice sites
1989 StandoutNobel
AGA technical review on perianal Crohn’s disease
2003
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆
2004
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
2011
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
1993
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
CXCR3 ligands in disease and therapy
2014
A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease
2006
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme
2000 StandoutNobel
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
2006
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
2006
Management of Crohn's Disease in Adults
2009 Standout
Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases
2008
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
2002
The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
2003
The limitations of corticosteroid therapy in Crohn’s disease
2001
Guidelines for the management of inflammatory bowel disease in adults
2004
Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria
2006
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
2011
Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis
2002
Therapeutic monoclonal antibodies
2000
Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease
2004
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
2006
A Case for Regulatory B Cells
2006
Interleukin-23 drives innate and T cell–mediated intestinal inflammation
2006
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease
2009
Autoimmunity and Anti-TNF-α Agents
2005
Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived O-glycans
2007
Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1–dependent pathway
2005
Interferon‐γ induces internalization of epithelial tight junction proteins via a macropinocytosis‐like process
2005
ANTIGEN SAMPLING ACROSS EPITHELIAL BARRIERS AND INDUCTION OF MUCOSAL IMMUNE RESPONSES
1996
Immunopathogenesis of the Acquired Immunodeficiency Syndrome
1985
Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice
2002
Critical Roles of Activation-Induced Cytidine Deaminase in the Homeostasis of Gut Flora
2002 StandoutScienceNobel
The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis
1988 StandoutScience
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut
2004 StandoutNobel
IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages
2007 Standout
THE B7 FAMILY REVISITED
2005 Standout
Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment
2005
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
2007
The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system
2014
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Defect in IgV gene somatic hypermutation in Common Variable Immuno-Deficiency syndrome
1998
Autocrine regulation of epithelial permeability by hypoxia: Role for polarized release of tumor necrosis factor α
1998
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
2016
The primary defect in experimental ileitis originates from a nonhematopoietic source
2006
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study
2005
Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
2005 StandoutNobel
Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease
2000
Host-microbiota interactions in inflammatory bowel disease
2012
Diagnosis and Treatment of Perianal Fistulas in Crohn Disease
2001
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Differential Roles of Segmented Filamentous Bacteria and Clostridia in Development of the Intestinal Immune System
1999
Rapid Infection of Oral Mucosal-Associated Lymphoid Tissue with Simian Immunodeficiency Virus
1999 StandoutScienceNobel
Cutting Edge: IL-23 Cross-Regulates IL-12 Production in T Cell-Dependent Experimental Colitis
2006
Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM.
1993
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006 Standout
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
2003
Anti-TNF Therapy and Malignancy – A Critical Review
2001
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
2008
New links to the pathogenesis of Crohn disease provided by genome-wide association scans
2007
Infliximab for the treatment of fistulas in patients with Crohn's disease
1999
Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.
2003
V. Polarized compartmentalization of antigen processing and Toll-like receptor signaling in intestinal epithelial cells
2002
CD1: Antigen Presentation and T Cell Function
2004
CD40 Ligand Gene Defects Responsible for X-Linked Hyper-IgM Syndrome
1993 Science
Lymphadenopathy-Associated Viral Antibody in AIDS
1984 StandoutNobel
Dendritic Cells Exposed to Human Immunodeficiency Virus Type-1 Transmit a Vigorous Cytopathic Infection to CD4 + T Cells
1992 StandoutScienceNobel
Discovery and Biology of IL-23 and IL-27: Related but Functionally Distinct Regulators of Inflammation
2006
Apoptosis in AIDS
1993 StandoutScienceNobel
IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6
2006
Lipopolysaccharide Activates Distinct Signaling Pathways in Intestinal Epithelial Cell Lines Expressing Toll-Like Receptors
2000
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Defective Lymphoid Development in Mice Lacking Jak3
1995 StandoutScienceNobel
Unraveling Function in the TNF Ligand and Receptor Families
1994 StandoutScienceNobel
Works of Lloyd Mayer being referenced
Mucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals
2013 Science
Expression of class II molecules on intestinal epithelial cells in humans
1991
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
2013
Mucosal Epithelium in Health and Disease
2005
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
1999 Standout
Complex Formation of the Interferon (IFN) Consensus Sequence-binding Protein with IRF-1 Is Essential for Murine Macrophage IFN-γ-induced iNOS Gene Expression
2003
Antigen processing and presentation by intestinal epithelial cells – polarity and complexity
2000
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
2001
Expression of class II molecules on intestinal epithelial cells in humans
1991
The Development of Animal Models of Inflammatory Bowel Disease
2000
Factors Affecting Antigen Uptake by Human Intestinal Epithelial Cell Lines
2000
A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis
2007
Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease
2006
Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease☆
2004
Non‐classical MHC class I molecules on intestinal epithelial cells: mediators of mucosal crosstalk
2005
Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells
2002
Oral tolerance and inflammatory bowel disease
2005
Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trial
2003
Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut
2011
The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells
2004
Epithelial: Lamina Propria Lymphocyte Interactions Promote Epithelial Cell Differentiation
2007
American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006
2007
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
2004
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 Standout
Regulatory T Cells
2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
2004
Unique Features of Antigen Presentation in the Intestinea
1992
The intestinal epithelial cell: processing and presentation of antigen to the mucosal immune system
1999
Oral Tolerance: New Approaches, New Problems
2000
Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells
2003
Induction of mucosal tolerance in Peyer‘s patch—deficient, ligated small bowel loops
2005
Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes
2009
Anti–Interleukin-12 Antibody for Active Crohn's Disease
2004
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
1999
Meeting Summary: Signal Transduction Pathways in Immune and Inflammatory Cells November 30–December 3, 2000, Amelia Island, Florida, U.S.A.
2003
Therapeutic potential of oral tolerance
2004
The Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience
2003
Enhanced Humoral Immunity in Common Variable Immunodeficiency after Long-Term Treatment with Polyethylene Glycol-Conjugated Interleukin-2
1994
Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial
2008
Crohn Disease: Frequency and Nature of CARD15 Mutations in Ashkenazi and Sephardi/Oriental Jewish Families
2004
CCFA Microbial–Host Interactions Workshop
2007
Immunoregulatory Lymphokines of T Hybridomas from AIDS Patients: Constitutive and Inducible Suppressor Factors
1984 Science
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
2005
Defects in CD8+ Regulatory T Cells in the Lamina Propria of Patients with Inflammatory Bowel Disease
2005
Evidence for a Defect in Switch T Cells in Patients with Immunodeficiency and Hyperimmunoglobulinemia M
1986
Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10
2005
I. Antigen presentation in the intestine: new rules and regulations
1998
Activation of CD8+ Regulatory T Cells by Human Placental Trophoblasts
2005
A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study
2003